Compare Baker Hughes Co (BKR) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baker Hughes Co vs Bristol-Myers Squibb Co — how do they compare? Baker Hughes Co trades at $64.94 (market cap $64.34B), while Bristol-Myers Squibb Co trades at $63.68 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 2× Baker Hughes Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BKR | BMY | |
|---|---|---|
Market Cap | $64.34B | $129.94B |
Sector | Energy | Health |
52-Week High | $69.67 | $65.89 |
52-Week Low | $42.51 | $42.60 |
Enterprise Value | $64.86B | $163.92B |
Dividend Yield | 1.42% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baker Hughes (BKR) trades at $64.94, up 1.35% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company demonstrates robust fundamentals with a P/E of 20.84, ROE of 16.47%, and positive cash flow trends. Recent news highlights major contract wins in subsea systems and LNG technology, signaling strong demand for its energy infrastructure solutions.
The outlook for BKR is positive, supported by analyst consensus and operational strength, though risks include integration challenges from acquisitions and potential volatility in oil & gas spending. The stock presents an opportunity for growth investors seeking exposure to energy technology, with a consensus price target of $73.25 implying potential upside.
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
